Outsourcing Pharma

OUTSOURCING PHARMA FEATURED ARTICLES

A Look At 2015 Outsourcing Trends And What To Expect In 2016
A Look At 2015 Outsourcing Trends And What To Expect In 2016

This has been another exciting year in outsourcing, as mergers, acquisitions, and other collaborations continued with CROs and CMOs moving toward functioning as strategic partners.

  • A Recap On 2014 Outsourcing Trends And What To Expect In 2015

    2014 was an exciting year in outsourcing. Several high profile mergers and acquisitions in both the CRO and CMO world will mean some familiar names will go through big changes — Huntingdon acquired Harlan, and PRA acquired RPS in the CRO world; Patheon acquired both DSM and Gallus Biopharma, and AMRI acquired Cedarburg and OsoBio in the CMO world.

  • Real/Future Information Risk of R&D – CROs

    The jury is still out on the ultimate impact of healthcare reform in general, and perhaps this impact is even murkier in the life sciences  space.  Certainly there will be very dramatic changes to the providers (hospitals, primary care, etc.) and payers (insurance companies, health plans, etc.), but it is more difficult to see exactly how the changes will manifest themselves for the remaining entities in the health sciences arena.

  • Maximizing Pipeline Value and Operational Efficiency through High Throughput Protein Expression

    At the core of every drug development program is the challenge to successfully express active, high quality product, and this is especially true of biologics. Indeed, very frequently drug developers are faced with protein expression issues, struggling to express a specific protein for months (and sometimes years) with varying degrees of success; low or no expression, insoluble expression, proteolytic clipping of the expressed protein or a combination thereof are examples of the hurdles encountered in product development efforts. Such challenges in protein expression are a major source of biopharmaceutical development delays, particularly as production strain development is typically performed in a linear and iterative fashion.

  • API Manufacturing: Strategic Partnering Preferences With CMOs Vary Among Small-Molecule, High-Potency And Biologic API

    Data compiled from a strategic partner survey for outsourcing commercial-scale drug substance projects in API manufacturing revealed the differences in how buyers think about strategic partnerships with contract manufacturers.

  • When Does A Supplier Become A Partner?

    Suppliers qualify for partner status when they share risk and responsibility, more than size and capabilities.

  • A Successful Externalization Strategy Demands Modernized Informatics

    Outsourcing can enable cost cutting and taking advantage of specialized expertise. But the complexity can also open the door to errors, rework, product delays, and compliance issues. Here are three items that should be on your data management short list when outsourcing.

  • Make Your CRO An Extension Of Your Internal Team

    The healthcare contract research outsourcing market is expected to grow from $25.1 billion in 2011 to $65 billion by 2018. Eight industry experts discuss how to turn your CRO into a strategic partner.

  • CROs And CMOs Continuing Drug Delivery Innovation

    In 2013 we can anticipate a new type of relationship emerging due to the steady demand among buyers of outsourced services for drug delivery support.

  • When It Comes To Outsourcing Relationships, Essential Qualities Vary

    Nice Insight’s survey asked outsourcing buyers to separate the essential qualities of an outsourcing relationship from the nonessential, and the essential qualities varied by the buyer category and business size.

  • 3 Keys To Successful Life Sciences Partnerships

    In Life Sciences business relationships, quality, reliability, and communication have to occur for both the client and the CMO to achieve their common goal.

  • How The Experts Assess CMO Attributes

    Life Science Leader magazine posed a series of questions to industry experts to gain insights on how they assess CMO attributes.

  • Biopharma Hiring Trends In The Right Direction

    Nice Insight’s pharmaceutical and biotechnology outsourcing survey, 10% indicated that innovativeness was the most important attribute when selecting a CRO or CMO. By Eric Langer, president and managing partner, BioPlan Associates, Inc. By Eric Langer, president and managing partner, BioPlan Associates, Inc.

  • Strategic Partnering For Innovation

    Nice Insight’s pharmaceutical and biotechnology outsourcing survey, 10% indicated that innovativeness was the most important attribute when selecting a CRO or CMO. By Kate Hammeke, research manager, Nice Insight

  • Expert Insight On Selecting A CRO

    Life Science Leader’s roundtable with seven experts provides insight to help gain greater understanding of the CRO selection process. By Rob Wright, Chief Editor, Life Science Leader magazine

  • Key Drivers For Outsourcing Partner Selection

    Each business has its own approach to outsourcing, from functional to full service, and often that approach is dependent on the requirements of a specific project. By Kate Hammeke, research manager, Nice Insight

More From Outsourcing Pharma